Protocol for Quantification of Integrated HIV DNA |
Authors: Sofie Rutsaert, Eva Malatinkova, Pawel Bonczkowski, Maja Kiselinova, Ward De Spiegelaere MATERIALS REAGENTS (Note 1) DNA extraction kit (Qiagen DNeasy Blood & Tissue kit, cat. 69504/69506) GoTaq® G2 DNA Polymerase (Promega, cat. M7845) Nuclease-free water (Qiagen, cat. 129114) dNTP mix (Promega, cat. U1511) Primers (see Table 1, ordered at Integrated DNA Technologies) LightCycler® 480 Probes Master, 2x concentrated (Roche Applied Science, cat. 04707494001) EQUIPMENT Thermal Cycler Applied Biosystems® 2720 (cat. 4359659) LightCycler® 480 System II (Roche, cat. 05015278001)
PROCEDURE (download as PDF) Isolate genomic DNA from the target cells using the DNA extraction kit. To estimate the volume of material used for the input in PCR reaction, one can either use a fixed number of input cell equivalents, e.g. 7500 equivalents per reaction as described by (1) Liszewski et al. 2009, , or adjust input to the amount of total HIV DNA, as estimated by a prior total HIV DNA quantification by real time or digital PCR (Note 2). INTRODUCTORY INFORMATIONThe Alu-HIV PCR is designed to quantify integrated proviral HIV DNA through a nested PCR setup of two consecutive PCR amplification rounds. In the first PCR forward primers are used for the human Alu repeat sequence in combination with a reverse primer, targeting an HIV specific sequence (fig. 1). This reaction only leads to a logarithmic amplification of HIV DNA when this DNA is integrated, and thus in the vicinity of an Alu sequence. Unintegrated linear or episomal HIV DNA is amplified in a linear faschion. The second PCR is composed of a quantitative PCR (qPCR) that amplifies an HIV specific sequence which is nested within the amplicon of the first PCR. To enable the differentiation of the background signal originating from unintegrated HIV DNA, a control is run in parallel using only an HIV reverse primer to mimic the kinetic PCR that would take place when unintegrated HIV DNA is present.
Figure 1: Schematic illustration of the Alu-PCR workflow. Showing the nested Alu-HIV PCR and the HIV-only PCR (background control).
|
THE SECOND PCR REACTION
ANALYSIS To assess the number of integrations per cell, the excel template (Fig. 2) can be used. The raw quantitative output of the Alu-HIV PCR as Cq values (Cycle of quantification, also termed Ct) should be inserted as described below.
Figure 2: the excel template
composed for Alu-HIV PCR quantification: the colored cells in the lower left quadrant require data input,
i.e. the correction factor as measured on the standard for calibration to assess the fold difference between
the observed and expected number of integrations/well, the total number of Alu-HIV replicates (required for accurate error estimation)
the number of cells per replicate reaction (assessed by a qPCR on a reference gene, e.g. RPP30),
and the raw quantification cycle (Cq)* values of the Alu-HIV PCR and the HIV only PCR. Note that negative reactions should be left empty
not to interfere with the analysis. After data input the results are shown in the shaded areas of the lower right quadrant,
|
*note that the Cq values are in some real-time PCR programs referred to as treshold cycle (Ct), crossing point (Cp) or take-off point (TOP)
| REFERENCES
Liszewski MK, Yu JJ, O'Doherty U: Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 2009;47:254-60.
url
| De Spiegelaere W, Malatinkova E, Lynch L, Van Nieuwerburgh F, Messiaen P, O'Doherty U, Vandekerckhove L: Quantification of Integrated HIV DNA by Repetitive-Sampling Alu-HIV PCR on the Basis of Poisson Statistics. Clin Chem 2014. url Yu JJ, Wu TL, Liszewski MK, Dai J, Swiggard WJ, Baytop C, Frank I, Levine BL, Yang W, Theodosopoulos T, O'Doherty U: A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology 2008;379:78-86. url Yun Z, Frederiksson E,Sönnerborg A: Quantification of human immunodeficiency virus type 1 proviral DNA by the TaqMan real-time PCR assay. Journal of Clinical Microbiology 2002;40:3883-3884. url NOTES
|